An investigation of the causes of cocrystal dissociation at high humidity

Journal of Pharmaceutical Sciences

Volumn 103, Issue 9, 2014, Pages 2859-2864

  Eddleston, Mark D ^a   Thakuria, Ranjit ^a,c   Aldous, Barry J ^b   Jones, William ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

co crystals; hydrates solvates; physical stability; solid state; solubility; X ray powder diffractometry

Indexed keywords

ADIPIC ACID; CAFFEINE; DICARBOXYLIC ACID; THEOPHYLLINE; DRUG; WATER;

ARTICLE; CRYSTAL; DISSOCIATION; DRUG SOLUBILITY; GRINDING; HUMIDITY; SOLID; SOLID PHASE SYNTHESIS; X RAY POWDER DIFFRACTION; CHEMISTRY; CRYSTALLIZATION; DRUG STABILITY; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY;

CAFFEINE; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; HUMIDITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; THEOPHYLLINE; WATER;

EID: 84906308243     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23865     Document Type: Article

References (35)

1. Caira MR,. 1992. Molecular complexes of sulfonamides. 2. 1:1 Complexes between drug molecules: Sulfadimidine-acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid. J Crystallogr Spectrosc Res 22 (2): 193-200.
2. Shan N, Zaworotko MJ,. 2008. The role of cocrystals in pharmaceutical science. Drug Discov Today 13 (9/10): 440-446.
3. Schultheiss N, Newman A,. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9 (6): 2950-2967.
4. Thayer AM., 2007. Form and function. C&EN News 85 (25): 17-30.
5. Almarsson O, Zaworotko MJ,. 2004. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines ? Chem Commun (17): 1889-1896.
6. Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, Desiraju GR, Dikundwar AG, Dubey R, Duggirala N, Ghogale PP, Ghosh S, Goswami PK, Goud NR, Jetti RRKR, Karpinski P, Kaushik P, Kumar D, Kumar V, Moulton B, Mukherjee A, Mukherjee G, Myerson AS, Puri V, Ramanan A, Rajamannar T, Reddy CM, Rodriguez-Hornedo N, Rogers RD, Row TNG, Sanphui P, Shan N, Shete G, Singh A, Sun CC, Swift JA, Thaimattam R, Thakur TS, Kumar Thaper R, Thomas SP, Tothadi S, Vangala VR, Variankaval N, Vishweshwar P, Weyna DR, Zaworotko MJ,. 2012. Polymorphs, salts, and cocrystals: What's in a name ? Cryst Growth Des 12 (5): 2147-2152.
7. Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Bailey Walsh RD, Rodriguez-Hornedo N, Zaworotko MJ,. 2003. Crystal engineering of the composition of pharmaceutical phases: Multiple-component crystalline solids involving carbamazepine. Cryst Growth Des 3 (6): 909-919.
8. Babu NJ, Sanphui P, Nangia A,. 2012. Crystal engineering of stable temozolomide cocrystals. Chem Asian J 7 (10): 2274-2285.
9. Karki S, Friščic̈ T, Fábián L, Laity PR, Day GM, Jones W,. 2009. Improving mechanical properties of crystalline solids by cocrystal formation: New compressible forms of paracetamol. Adv Mater 21 (38-39): 3905-3909.
10. Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzman HR, Almarsson O,. 2003. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 125 (28): 8456-8457.
11. Babu NJ, Nangia A,. 2011. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des 11 (7): 2662-2679.
12. Friščic̈ T, Jones W,. 2010. Benefits of cocrystallization in pharmaceutical materials science: An update. J Pharm Pharmacol 62 (11): 1547-1559.
13. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodriguez-Hornedo N,. 2013. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm 453 (1): 101-125.
14. Good DJ, Rodriguez-Hornedo N,. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 9 (5): 2252-2264.
15. Blagden N, de Matas M, Gavan PT, York P,. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 59 (7): 617-630.
16. Eddleston MD, Sivachelvam S, Jones W,. 2013. Screening for polymorphs of cocrystals: A case study. CrystEngComm 15 (1): 175-181.
17. Eddleston MD, Lloyd GO, Jones W,. 2012. Cocrystal dissociation and molecular demixing in the solid state. Chem Commun 48 (65): 8075-8077.
18. Arhangelskis M, Lloyd GO, Jones W,. 2012. Mechanochemical synthesis of pyrazine:dicarboxylic acid cocrystals and a study of dissociation by quantitative phase analysis. CrystEngComm 14 (16): 5203-5208.
19. Trask AV, Motherwell WDS, Jones W,. 2005. Pharmaceutical cocrystallization: Engineering a remedy for caffeine hydration. Cryst Growth Des 5 (3): 1013-1021.
20. Trask AV, Motherwell WDS, Jones W,. 2006. Physical stability enhancement of theophylline via cocrystallization. Int J Pharm 320 (1-2): 114-123.
21. Eddleston MD, Madusanka N, Jones W., Submitted for publication.
22. Bučar DK, Henry RF, Lou XC, Borchardt TB, Zhang GGZ,. 2007. A "hidden" co-crystal of caffeine and adipic acid. Chem Commun (5): 525-527.
23. Friščic̈ T, Trask AV, Jones W, Motherwell WDS,. 2006. Screening for inclusion compounds and systematic construction of three-component solids by liquid-assisted grinding. Angew Chem Int Ed Engl 45 (45): 7546-7550.
24. Chiarella RA, Davey RJ, Peterson ML,. 2007. Making co-crystals-The utility of ternary phase diagrams. Cryst Growth Des 7 (7): 1223-1226.
25. Childs SL, Rodriguez-Hornedo N, Reddy LS, Jayasankar A, Maheshwari C, McCausland L, Shipplett R, Stahly BC,. 2008. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. CrystEngComm 10 (7): 856-864.
26. Jayasankar A, Reddy LS, Bethune SJ, Rodriguez-Hornedo N,. 2009. Role of cocrystal and solution chemistry on the formation and stability of cocrystals with different stoichiometry. Cryst Growth Des 9 (2): 889-897.
27. Yalkowsky SH, He Y,. 2003. Handbook of aqueous solubility data. Boca Raton, Florida: CRC Press LLC, pp 1512.
28. Rodriguez-Hornedo N, Nehm SJ, Seefeldt KF, Pagan-Torres Y, Falkiewicz CJ,. 2006. Reaction crystallization of pharmaceutical molecular complexes. Mol Pharm 3 (3): 362-367.
29. Nehm SJ, Rodriguez-Spong B, Rodriguez-Hornedo N,. 2006. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des 6 (2): 592-600.
30. Jayasankar A, Good DJ, Rodriguez-Hornedo N,. 2007. Mechanisms by which moisture generates cocrystals. Mol Pharm 4 (3): 360-372.
31. Good DJ, Rodriguez-Hornedo N,. 2010. Cocrystal eutectic constants and prediction of solubility behavior. Cryst Growth Des 10 (3): 1028-1032.
32. Chadwick K, Davey R, Sadiq G, Cross W, Pritchard R,. 2009. The utility of a ternary phase diagram in the discovery of new co-crystal forms. CrystEngComm 11 (3): 412-414.
33. Cassidy AMC, Gardner CE, Jones W,. 2009. Following the surface response of caffeine cocrystals to controlled humidity storage by atomic force microscopy. Int J Pharm 379 (1): 59-66.
34. Hsu IN, Gellert RW,. 1983. The 1:1 crystal complex of salicylic acid and urea. J Crystallogr Spectrosc Res 13 (1): 43-48.
35. Bond AD, Boese R, Desiraju GR,. 2007. On the polymorphism of aspirin: Crystalline aspirin as intergrowths of two "polymorphic" domains. Angew Chem Int Ed Engl 46 (4): 618-622.